Hendrik Jan Ankersmit (Managing Board) is the scientific founder of Aposcience AG. He is a thoracic surgeon working at the Medical University of Vienna at the Vienna General Hospital.

Andreas Kronberger (Managing Board) covered national and international management positions in various pharmaceutical companies for more than 30 years. Most recently he served as General Manager for Baxter Healthcare Österreich GmbH and Actelion Pharmaceuticals Austria GmbH, a Janssen Company of Johson & Johnson. At Aposcience he is responsible for finances since 2016.
Ghazaleh Gouya (Chief Medical Officer) Board certified in Internal Medicine, Cardiology and Clinical Pharmacology, MD, and awarded Associate Professor in Internal Medicine, with more than 18 years of clinical and research experience in academia as well as for pharmaceutical companies. Ghazaleh takes leadership for the clinical development in the selected therapeutic areas for ApoScience.
Michael Mildner (Chief Scientific Officer) is associated professor at the Department of Dermatology, Medical University of Vienna with long lasting experience in skin biology and cutaneous tissue regeneration. He received his PhD from the University of Leiden for his studies on in vitro skin models. His main research interests include wound healing, keratinocyte differentiation epithelial barrier formation as well as exploring mechanisms of tissue regeneration.
Helmut Hofbauer (Head of Regulatory Affairs), Dr phil. He is Assistant to the Board of Directors.
Maria Laggner (Quality Assurance) joined the R&D division in January 2018. She obtained her PhD degree in molecular biology and performed ophthalmic and stem cell research. Currently, she is elucidating the modes of actions and novel indications of APOSEC. Beyond basic research, she is implicated in quality assurance and in charge of data security.
Alfred Gugerell (Clinical Development) is responsible for clinical development and acts as internal project manager of the clinical phase II study MARSYAS II. Furthermore, he is data security coordinator and supports the quality management. He has a PhD in biology and performed research on skin tissue regeneration, vascular, cutaneous wound healing, and on stem cell transplantation after myocardial infarction.
Latest News

Approval for clinical phase II study in DFU by Austrian health agency



US Patent Office issues Allowance for APOSEC Patent